B
Bull
Bull · 25%APUS
$2.05
Scenario price
$2.685
-0.044 (-1.65%)At close
Loading chart…
- High
- 2.752
- Open
- 2.670
- VWAP
- 2.66
- Volume
- 15.08K
- Mkt Cap
- —
- Low
- 2.530
- Amount
- 40.05K
- EV/EBITDA, TTM
- 0.00
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
AI analysis of Apimeds Pharmaceuticals US Inc (APUS)
SellApimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
Valuation Metrics
The current forward P/E ratio for Apimeds Pharmaceuticals US Inc (APUS) is 0.00, compared to its 5-year average forward P/E of 0.00.
Alphio AI Price Scenarios for APUS
Scenario prices are the last monthly forecast band of the current year. Probabilities are fixed model weights (25 / 50 / 25), not guarantees.
Events Timeline
News
8.510-13NewsfilterMindWave Lists NILA Token on Pionex Exchange
- 7.510-09Newsfilter
MindWave Signs Three Blockchain Agreements Across Diverse Industries
8.507-28GlobenewswireMindChain: The World's First Fully Insured Blockchain Launching Soon
- 8.507-28Newsfilter
MindWave Launches World's First Fully Insured Blockchain
8.505-06NASDAQ.COMApimeds Reaches Settlement with Inscobee, Clearing Path for Merger
APUS FAQ — answered by Alphio AI
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions. It operates in the Healthcare sector.
Apimeds Pharmaceuticals US Inc is not a good buy right now due to its significant financial losses and poor technical indicators. The current price is $2.68, and the company has reported a staggering net income loss of $35,059,852 in Q1 2026. Additionally, the RSI is at 26.149, indicating that the stock is oversold, but this does not suggest a buying opportunity given the ongoing financial instability.
Community
More ↗No posts yet
Sign up or log in to join the discussionRelated articles
- Stock Market After the 2026 Midterms: What a Democratic Congress Means for InvestorsDemocrats swept Congress in the 2026 midterms. See how stocks reacted, what history says about post-midterm returns, and which sectors face new risks.
- How to Rebalance a Concentrated Stock Portfolio in 2026: Mag7 Drift, Tax-Aware Trims, and Practical Rebalance a concentrated stock portfolio in 2026: Mag7 drift risk, 5pp bands, tax-aware trims, RSP/IWM diversifiers, and single-name caps.
- Small Cap Stocks Investing Guide 2026: Russell 2000, Fed Hikes, and the Financing TradeSmall-cap stocks investing guide 2026: Russell 2000 vs S&P, IWM rate sensitivity, floating-rate debt, Fed hikes, valuation discounts, and a practical checklist.
This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.